Sanofi

Report: Some sponsors more prepared to lead the way in personalized medicine than others

Monday, April 18, 2011 08:05 AM

As the pharmaceutical industry’s investment in personalized medicine leads to development of an increasing number of targeted therapies, particularly for cancer patients, some drug sponsors have shown greater commitment and more structure in their approach than others, according to a new report by consulting firm Diaceutics.

More... »

Innovative paperless clinical trial study highlights time and cost savings

Friday, April 15, 2011 11:11 AM

Using interoperable digital identities, digital signatures and cloud computing can accelerate the initiation of a clinical trial and also lower costs, report a group of government and industry cancer researchers. They participated in the phase I of a pilot study that used interoperable digital identities and cloud-based digital signatures to eliminate reliance on paper forms in clinical trials.

More... »

Shanghai Pharmaceuticals inks $3 billion in overseas contracts

Thursday, April 14, 2011 01:07 PM

Shanghai Pharmaceuticals will ink more than $3.06 billion worth of procurement contracts with 69 worldwide pharmaceutical companies this year, according to Global Times.

More... »

Sanofi-Aventis seeks buyer for dermatology unit

Thursday, April 14, 2011 11:54 AM

French drugmaker, Sanofi-aventis, is seeking a buyer for its U.S. dermatology business that could amount to a $433 million sale, according a Bloomberg report.

More... »

Neuroscience drug development slows, requires funding

Tuesday, March 29, 2011 11:49 AM

Many European pharmaceutical companies have significantly reduced their workflow in the realm of neuroscience, according to Fierce Biotech. Companies are challenged with a high risk of trial failure while investors demand new products. 

More... »

Sanofi collaborates with Columbia University

Friday, March 25, 2011 11:28 AM

Sanofi-aventis has entered into a collaboration with Columbia University Medical Center to develop diabetes drugs, according to PharmaTimes.

More... »

Sanofi/Regeneron's aflibercept fails trial

Thursday, March 17, 2011 01:06 PM

Sanofi-aventis and partner Regeneron have suffered a setback with their investigational agent aflibercept failing a late-stage trial for non-small cell lung cancer (NSCLC), according to PharmaTimes.

More... »

Pfizer talking with CROs to fill R&D hub

Wednesday, March 16, 2011 12:33 PM

A U.K. task force—assembled to salvage as many R&D jobs at Sandwich as it can before Pfizer completes its planned exit—has confirmed that the pharma giant is in discussions with CROs that may step in to hire some of the 2,400 workers being let go, according to Fierce Biotech.

More... »

FDA approves generic Taxotere

Friday, March 11, 2011 01:47 PM

Hospira has won approval for the first U.S. generic version of Sanofi-aventis’ Taxotere cancer drug, according to a Reuters report.

More... »

Genzyme sells pharmaceuticals segment

Monday, March 7, 2011 10:49 AM

Cambridge, Mass.-based Genzyme has completed the sale of its pharmaceutical intermediates business to Germany's International Chemical Investors Group for an undisclosed amount, according to BIOSmartBrief.

More... »